RESUMO
Nomifensine, an antidepressive agent acting like a dopamine agonist, was investigated in a randomized double-blind comparison with amitriptyline in 29 patients fulfilling the RDC criteria for major depression. The dosage was 150 mg daily in both treatment groups. Assessments were made at weekly intervals for 6 weeks with the Comprehensive Psychopathological Rating Scale. No significant difference could be demonstrated between the two drugs in overall therapeutic efficiency, and only one item, Fatiguability, differed significantly in favour of amitriptyline. Physical and laboratory variables showed no statistically significant differences. Neither drug elicited serious unwanted effects.
Assuntos
Amitriptilina/uso terapêutico , Transtorno Depressivo/tratamento farmacológico , Isoquinolinas/uso terapêutico , Nomifensina/uso terapêutico , Adulto , Idoso , Amitriptilina/efeitos adversos , Ensaios Clínicos como Assunto , Método Duplo-Cego , Fadiga/induzido quimicamente , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Nomifensina/efeitos adversos , Nomifensina/farmacologia , Escalas de Graduação PsiquiátricaRESUMO
Heterozygous mice of the T190/tf translocation stock, having one superlong and one short marker chromosome, involving the H-2-bearing ninth linkage group, were typed by membrane fluorescence and cytotoxicity tests against a panel of H-2 antisera. Marker-positive segregants differed serologically from their marker-negative siblings. Lymphomas were induced by the Moloney virus in (A.CA x T190/tf)F1 mice. A combined serological and cytogenetic analysis showed that the tumors could be subdivided into two main classes, corresponding to marker-positive and marker-negative types. Each lymphoma was relatively stable with regard to karyologic and correlated antigenic characteristics during serial passage in (A.CA x T190/tf)F1 mice. This system opens new possibilities to study the genetic mechanisms of H-2 antigenic variation, demonstrated previously in heterozygous tumors.
